Target Dosing for Fluvoxamine (Luvox)
For adults with OCD, start fluvoxamine at 50 mg daily at bedtime and titrate in 50 mg increments every 4-7 days to an effective dose of 100-300 mg/day, with doses above 100 mg split into two divided doses (larger dose at bedtime). 1
Adult Dosing
The FDA-approved dosing strategy is straightforward:
- Starting dose: 50 mg once daily at bedtime
- Titration: Increase by 50 mg every 4-7 days as tolerated
- Effective range: 100-300 mg/day (established in controlled trials)
- Maximum dose: 300 mg/day
- Dosing schedule: Total daily doses >100 mg should be split into two divided doses, with the larger dose given at bedtime 1
Research supports that higher doses (100-150 mg daily) achieve better response rates (73.7%) compared to lower doses of 50-75 mg (47.1%), with most responders evident by 6 weeks 2. This aligns with the FDA label's recommendation to titrate to the 100-300 mg range.
Pediatric Dosing (Ages 8-17)
For children and adolescents with OCD, start at 25 mg daily at bedtime and titrate in 25 mg increments every 4-7 days, with maximum doses of 200 mg/day for children up to age 11 and 300 mg/day for adolescents. 1
Key pediatric considerations:
- Starting dose: 25 mg once daily at bedtime
- Titration: Increase by 25 mg every 4-7 days
- Children (ages 8-11): Maximum 200 mg/day; therapeutic effect in females may be achieved with lower doses
- Adolescents (ages 12-17): Maximum 300 mg/day (same as adults)
- Dosing schedule: Total daily doses >50 mg should be split into two divided doses, with the larger dose at bedtime 1
The pharmacokinetic rationale is critical here: children demonstrate 2-3 fold higher steady-state plasma concentrations than adolescents, with female children showing 1.5-2.7 fold higher AUC and Cmax compared to male children 1, 3. This explains why lower maximum doses are recommended for younger children and why females may respond to lower doses. Adolescents show similar fluvoxamine exposure to adults at 300 mg/day, justifying the same maximum dose 1.
For adolescent depression specifically (though fluvoxamine is FDA-approved only for OCD), guidelines suggest starting at 50 mg, increasing in 50 mg increments to an effective dose of 150 mg with a maximum of 300 mg 4. However, this is off-label use.
Elderly and Hepatically Impaired Patients
For elderly patients or those with hepatic impairment, use slower titration and lower doses due to 30-50% decreased clearance. 1
The pharmacokinetic changes are substantial:
- Elderly patients show 40% higher maximum plasma concentrations
- Elimination half-life increases from 13.6-15.6 hours in young adults to 17.4-25.9 hours in elderly
- Clearance is reduced by approximately 50% in elderly patients 1
- Hepatic dysfunction causes a 30% decrease in fluvoxamine clearance 1
Therefore, start at lower doses (25 mg daily) and titrate more slowly (every 7-10 days rather than every 4-7 days) in these populations. While the FDA label doesn't specify exact doses, the pharmacokinetic data mandates caution 1.
Critical Dosing Considerations
Drug Interactions
Fluvoxamine is a potent CYP1A2 inhibitor and moderate CYP3A4 and CYP2C19 inhibitor. When combined with clozapine, fluvoxamine reduces clozapine clearance by 56.5%, requiring substantial dose reductions of clozapine 5. Allow at least 14 days between discontinuing MAOIs and starting fluvoxamine, and vice versa 1.
Adverse Event Monitoring
Higher starting doses (rather than the recommended starting doses) increase the risk of deliberate self-harm and suicide-related events 4. Monitor closely during the first few months and at dose changes, though telephone contact may be as effective as face-to-face visits 4.
Discontinuation
Always taper slowly when discontinuing to avoid withdrawal effects 4.
Pregnancy Considerations
When treating pregnant women in the third trimester, carefully weigh risks versus benefits and consider tapering, as neonates may develop complications requiring prolonged hospitalization 1.